Partow Kebriaei on Monitoring Patients for Cytokine Release Syndrome
PARTOW KEBRIAEI, MD
Tuesday, February 28, 2017
Partow Kebriaei, MD, of MD Anderson Cancer Center, discusses what to be aware of when treating patients who have undergone CAR T-cell therapies.
Cytokine release syndrome (CRS) and other neurotoxicities often occur within the first 2 weeks after infusion of CAR T-cell therapy. During this time, symptoms such as fever may not seem alarming but can be indications of CRS. It is important to carefully monitor these patients through vitals, daily weight, and mental status. Close observation during the first weeks after the CAR T-cell therapy is necessary to catch CRS in these patients.